Chief Information Officer
Tom O'Leary is the chief information officer at ICON and has over 20 years of experience in the pharmaceutical industry. Tom joined the company in 2001 as a manager of data management and has held various leadership positions.
Prior to ICON, Tom worked for SmithKline Beecham and later GlaxoSmithKline and held positions in data management, project management and resource management. Tom holds a degree in medicinal chemistry and a masters in data management from Kingston University in Surrey and is a member of the Royal Society of Chemistry.
Mark Roseman, D.Sc.
Senior Vice President, Clinical Operations
Dr. Mark Roseman is the senior vice president of clinical operations at Medpace, where he is responsible for oversight of all CRO clinical operations. Mark has more than 25 years of experience in the clinical research industry, specializing in project management, scientific operations, and business development.
Prior to Medpace, Mark worked at Pharmaceutical Product Development (PPD) as vice president of clinical operations, where he provided oversight to all project management and clinical operations staff based in North Carolina and supervised the oncology, cardiovascular, anti-infective, and respiratory therapeutic areas.
Before entering the CRO industry, Mark spent six years at CIBA Vision and five years working on a National Eye Institute grant at the Framingham Heart Study. While at CIBA Vision, Mark supervised all data management, clinical operations, biostatistics, and medical writing activities.
Mark has also held senior management positions at i3, Kendle/INC, and ICON where he played a key role in supporting reorganization efforts.
Mark holds a Master of Public Health (MPH) and Doctor of Science in epidemiology from Boston University.
Bhooshi de Silva
Senior Vice President, Corporate Development and Strategy
Bhooshi serves as senior vice president of corporate development and strategy for PPD and is a member of PPD’s executive leadership team. Bhooshi is responsible for leading the strategy, corporate development (M&A, partnerships), and enterprise data and innovation functions. Bhooshi partners with the senior leadership team on key strategic initiatives, leads PPD’s data and disruptive innovation priorities, and plays an important role in driving the company’s evolution and growth. Since joining PPD in 2014, Bhooshi has led the organization in completing several strategic partnerships and acquisitions, and in strengthening and expanding the company’s capabilities in priority focus areas.
Prior to PPD, Bhooshi spent 15 years in the biopharmaceutical industry, where he held several leadership positions. He started his career at Pfizer, where his roles spanned R&D portfolio management, U.S. commercial development, and U.S. customer strategy and negotiations. In 2009, Bhooshi was named vice president of business development evaluation and strategy, leading a team in the evaluation of licensing, acquisitions and corporate strategic initiatives for Pfizer.
Bhooshi was also head of corporate development, corporate strategy and head of International at Optimer Pharmaceuticals, where he played an integral role in the commercialization strategy and Optimer’s sale to Cubist Pharmaceuticals in 2013. He has an impressive track record of achievement in corporate strategic initiatives and M&A transactions on both the buy and sell sides.
Bhooshi holds degrees in finance, economics and engineering from Stanford University, London School of Economics and Imperial College of Science & Technology in London.
PRA Health Sciences
Executive Vice President, Product Registration, Americas
Michael Brooks is the executive vice president of product registration at PRA, where he is responsible for overall client satisfaction, project delivery, staff development, continuous improvement, and innovation in the Americas.
As a member of the executive leadership team, Michael participates in the development of PRA’s short- and long-term strategic direction, implements innovations and change, supports the hiring and continuous development of talent, and achieves corporate business and operational targets.
Michael has over 20 years of experience working across the full drug development lifecycle in product development, project management, operations, and driving strategic innovation. He is regarded across the industry for developing groundbreaking operational strategies and deploying state of the art technologies to accelerate drug development activities.
Prior to PRA, Michael worked at Pharmaceutical Product Development (PPD) where he held executive leadership positions in project management, global hematology and oncology, and site intelligence and innovation. He holds a bachelor of science degree from North Carolina State University.
Chief Information Officer
Rachel is the chief information officer (CIO) at Syneos Health, where she is responsible for the company’s enterprise technology efforts and collaborating with the business to harvest actionable data insights to enable biopharmaceutical acceleration. Rachel is also responsible for designing a go-forward infrastructure to support employee, customer, and marketplace demands for the new company, which came together through the merger of INC Research and inVentiv Health.
Rachel has more than 20 years of life sciences IT experience and a proven track record for developing solutions that improve efficiencies and customer service, ultimately enabling patient care solutions.
Prior to the INC Research and inVentiv Health merger, Rachel served as the CIO for inVentiv Health where she was responsible for the company’s technology portfolio. She joined inVentiv Health in 2014 as CIO for the clinical division where she managed the division’s technology priorities and all systems including those supporting study start-up, investigator identification, and trial monitoring and documentation.
Earlier in her career, Rachel spent several years as the CIO and senior vice president of marketing at Optimer Pharmaceuticals and held multiple senior level roles at Pfizer, Inc.
Rachel holds an MBA from Columbia Business School where she graduated with highest honors, and a bachelor of arts from the University of Pennsylvania where she graduated summa cum laude.
Vice President, Commercial Strategy
Brett is the vice president of commercial strategy for product and opportunity development at UBC. He is responsible for sales, marketing, and investments within UBC to drive strategic market and organizational growth strategies across clinical development, late stage peri and post approval research, and commercial launch of specialty therapies. Brett has a proven track record of making intelligent investments in people, processes, external relationships, and technology to drive the development of new products and services.
Brett has over 20 years of experience delivering innovative commercial and services solutions in the pharmaceutical industry. Since joining UBC in 2008, Brett has also held leadership positions supporting sales, marketing, proposals, pricing, commercial analytics and insights, and product development.
Prior to UBC, Brett spent nine years with Covance, where he successfully helped clients find new ways to bring novel therapies to market, inform safe and appropriate use of biopharmaceuticals, and optimize access and adherence to these therapies.
Brett holds an MBA in Pharmaceuticals from Saint Joseph’s University, as well as bachelor degrees in neuroscience and cognitive psychology from Allegheny College.
President, Align Clinical CRO and
General Manager, Veeva Vault CDMS
Henry Levy has nearly 25 years of experience transforming the way the biopharmaceutical industry improves patient health. He currently serves as general manager of Veeva Vault CDMS at Veeva Systems where he has overall responsibility for the Veeva Vault CDMS product. Previously, he was chief commercial officer at PPD, one of the world’s largest CROs, and head of Accenture’s global life sciences R&D practice.
As president for Align Clinical CRO, Henry is responsible for working with members to define the strategy and focus for the group’s initiatives.